Feb. 8, 2021 13:00 UTC
CARLSBAD, Calif.--(BUSINESS WIRE)-- Lineage Cell Therapeutics, Inc.(NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it has entered into an exclusive option and license agreement with Neurgain Technologies, Inc. (Neurgain), a medical device company that is commercializing technology developed by neurosurgeons at the University of California San Diego (UC San Diego). Under the terms of the agreement, Lineage and Neurgain will collaborate on the clinical testing of Neurgains novel Parenchymal Delivery Injection (PDI) system, which is designed to allow for the administration of cells to the spinal cord without stopping the patients respiration. Elimination of the need to stop respiration during surgery is expected to reduce the complexity, risk, and variability of administering cells to the area of injury. Lineage also will be hosting an OPC1 Investor and Analyst Day on February 22, 2021 to provide details on recent OPC1 milestones and plans for 2021.
Lineage will evaluate the Neurgain PDI systems ability to safely and effectively deliver OPC1, Lineages allogeneic oligodendrocyte progenitor cell (OPC) transplant, to the spinal cord in both preclinical and clinical studies beginning this year. If results from the PDI system are positive, then Lineage may exercise its option to enter into a pre-negotiated license and commercialization agreement with Neurgain. Pursuant to that agreement, Lineage may integrate the PDI system into a later-stage clinical trial and if approved, commercial use of OPC1 for the treatment of patients with a cervical spinal cord injury. There currently are no U.S. Food and Drug Administration (FDA) approved treatments for spinal cord injury.
Brian M. Culley, Lineage CEO stated, Several months ago, we announced we had significantly improved the process for manufacturing OPC1, leading to large increases in purity and scale. More recently, we successfully developed a new 'thaw-and-inject' formulation, eliminating the commercially undesirable steps of handling and preparing cells one day prior to their use. Today, we are announcing another valuable improvement to the OPC1 program: access to a novel and convenient delivery system, which reduces a significant technical hurdle of conducting a larger-scale clinical trial. The Neurgain PDI offers an easier, potentially safer, and commercially more attractive option to treat SCI patients and is preferable to the complicated gantry utilized in an earlier study. It also will allow us to incorporate our new 'thaw-and-inject' formulation of OPC1, thereby enabling faster patient enrollment via access to a larger number of clinical trial sites. Most importantly, the PDI can eliminate the need for a patients respirator to be turned off during the procedure, facilitating a measured and targeted transplantation of cells to the affected area.
We look forward to collaborating with Lineage on their novel OPC1 program and demonstrating the value that Neurgains PDI system can provide for the effective delivery of cell therapies in general and for the treatment of spinal cord injury in particular, stated Michael Krupp, Neurgain CEO.
Brian Culley added, Similar to our alliance with Gyroscope Therapeutics for the Orbit Subretinal Delivery System, this new partnership with Neurgain delivers on our stated commitment to identifying and deploying optimal combinations of allogeneic cell therapies, modern manufacturing techniques, and superior delivery solutions in pursuit of our goal of becoming the pre-eminent allogeneic cell transplant company.
The Neurgain PDI System has been designed to provide specific, on-target delivery of cells with accurate dosing. The PDI system is more compact than existing devices and it is attached directly to the patient during the procedure. It is comprised of a platform and manipulator with a disposable magnetic needle assembly. This novel delivery system is expected to provide a significant improvement in usability and precision when compared to the methods and tools utilized to deliver OPC1 cells in the completed phase 1/2a SCiStar study of OPC1 for the treatment of acute cervical SCI.
About Spinal Cord Injuries
A spinal cord injury (SCI) occurs when the spinal cord is subjected to a severe crush or contusion and frequently results in severe functional impairment, including limb paralysis, aberrant pain signaling, and loss of bladder control and other body functions. There are approximately 18,000 new spinal cord injuries annually in the U.S. There are no FDA-approved drugs specifically for the treatment of SCI. The cost of a lifetime of care for a severe spinal cord injury can be as high as $5 million.
About OPC1
OPC1 is an oligodendrocyte progenitor cell (OPC) transplant therapy designed to provide clinically meaningful improvements in motor recovery in individuals with acute spinal cord injuries (SCI). OPCs are naturally occurring precursors to the cells which provide electrical insulation for nerve axons in the form of a myelin sheath. The OPC1 program has been partially funded by a $14.3 million grant from the California Institute for Regenerative Medicine (CIRM). OPC1 has received Regenerative Medicine Advanced Therapy (RMAT) designation and Orphan Drug designation from the FDA.
About the OPC1 Clinical Study
The SCiStar Study of OPC1 is an open-label, 25-patient, single-arm trial testing three sequential escalating doses of OPC1 administered 21 to 42 days post-injury in patients with subacute motor complete (AIS-A or AIS-B) cervical (C-4 to C-7) acute spinal cord injuries (SCI). Patient enrollment in this study is complete; 96% of patients reported one level of improved motor function and 33% of patients reported two levels of improved motor function. Patients continue to be evaluated on a long-term basis. Patients enrolled in the study had experienced severe paralysis of the upper and lower limbs. The primary endpoint in the study was safety. Secondary outcome measures included neurological function measured by upper extremity motor scores (UEMS) and motor level on International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) examinations through 365 days post-treatment.
About Neurgain Technologies, Inc.
Neurgain Technologies (NGT) was founded in 2013 to develop technologies focused on the treatment of neurodegenerative diseases and neuropathic pain. Neurgain is developing a novel gene therapy technology and delivery devices to treat chronic neuropathic pain and spinal spasticity. 7-8% of the population suffers from Neuropathic Pain. Current therapeutic management is not working: Drugs in use have poor efficacy, and cause undesirable side effects such as resistance, addiction, and other disorders. NGTs mission is to positively impact this problem by means of our patented innovation to provide a therapy that works and improves the patients quality of life. The Company is developing two assets: 1. Spinal subpial gene delivery platform (device), 2. Pre-clinical gene therapy for severe neuropathic pain. NGT plans to license the platform delivery technologies to multiple pharma/biotech which are developing gene or cell therapies in CNS. Neurgains business strategy involves the out-licensing of spinal cord delivery technology and clinical development of a gene therapy for neuropathic pain and chronic spasticity. For more information, please visit https://neurgaintech.com/.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineages programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineages clinical programs are in markets with billion dollar opportunities and include three allogeneic (off-the-shelf) product candidates: (i) OpRegen, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC, an allogeneic dendritic cell therapy platform for immuno-oncology and infectious disease, currently in clinical development for the treatment of non-small cell lung cancer. For more information, please visit http://www.lineagecell.com or follow the Company on Twitter @LineageCell.
Forward-Looking Statements
Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as believe, may, will, estimate, continue, anticipate, design, intend, expect, could, plan, potential, predict, seek, should, would, contemplate, project, target, tend to, or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating to the potential benefits of using the Neurgain PDI device. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Lineages actual results, performance, or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including risks and uncertainties inherent in Lineages business and other risks in Lineages filings with the Securities and Exchange Commission (the SEC). Lineages forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. Further information regarding these and other risks is included under the heading Risk Factors in Lineages periodic reports with the SEC, including Lineages Annual Report on Form 10-K filed with the SEC on March 12, 2020 and its other reports, which are available from the SECs website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Lineage undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210208005187/en/
- Hungarian Spinal Cord Injury Patient - Stem Cell Treatment Experience - May 7th, 2011 [May 7th, 2011]
- Stem cell treatment for Spinal Cord Injury (SCI)-Osama - May 8th, 2011 [May 8th, 2011]
- Spinal Cord Injury Patient after Stem Cell Treatment - Juan Carlos Murillo - May 10th, 2011 [May 10th, 2011]
- Spinal Cord Injury patient 10 years after injury after Stem Cell Treatment - May 10th, 2011 [May 10th, 2011]
- Rap Toward a Cure for Spinal Cord Injury - May 11th, 2011 [May 11th, 2011]
- Christopher "Kit" Bond - Spinal Cord Injury Stem Cell Patient - May 20th, 2011 [May 20th, 2011]
- Stem Cell Treatment - Spinal Cord Injury (2) - May 21st, 2011 [May 21st, 2011]
- Spinal Cord Injury-After Treatment, Pt was completely paralyzed (2) - May 22nd, 2011 [May 22nd, 2011]
- Spinal Cord Injury-After Treatment, Pt was completely paralyzed (1) - May 23rd, 2011 [May 23rd, 2011]
- Dogs recover following new treatment for spinal cord injury - June 2nd, 2011 [June 2nd, 2011]
- Spinal Cord Injury Rehabiliation Success Story - June 3rd, 2011 [June 3rd, 2011]
- Stem Cells for Spinal Cord Injury: Community Outreach San Diego 2011 - Trish Stressman - June 7th, 2011 [June 7th, 2011]
- Stroke Client Gains Strength and Mobility in North Palm Beach Florida - June 9th, 2011 [June 9th, 2011]
- Spinal Cord Injury Chicago Rehabilitation Lokomat - June 10th, 2011 [June 10th, 2011]
- Spinal Cord Injury Treatment With Stem Cells - June 11th, 2011 [June 11th, 2011]
- Spinal Cord Injury Patient after Stem Cell Treatment - Wesley Hixen - June 12th, 2011 [June 12th, 2011]
- Stem Cell Therapy for Spinal Cord Injury - Injured Airline Pilot Flies Again - June 13th, 2011 [June 13th, 2011]
- David Chen: How would stem-cell therapies work in the treatment of spinal cord injuries? - June 17th, 2011 [June 17th, 2011]
- William Rader MD - Paralyzed Spinal Cord Injury Patient Walks Again - June 29th, 2011 [June 29th, 2011]
- The Spinal Cord Injury Treatment Team - July 4th, 2011 [July 4th, 2011]
- Introduction to the Bioness H200 Hand Rehabilitation System - July 14th, 2011 [July 14th, 2011]
- Organ repair using own stem cells -- brain, heart - Future Health keynote speaker - July 15th, 2011 [July 15th, 2011]
- 2011 Shriners Ride for Kids, Salt Lake City Utah. - July 17th, 2011 [July 17th, 2011]
- Degenerative Disc Disease: C5-C6 c6-C7 Treatment - July 18th, 2011 [July 18th, 2011]
- Rehabilitation Institute of Michigan's 60 Anniversary TV Commercial - July 18th, 2011 [July 18th, 2011]
- California Spinal Cord Injury Attorney: Obtaining damages for lifetime care. - July 19th, 2011 [July 19th, 2011]
- Physical and Mental Adjustments After a Spinal Cord Injury - July 19th, 2011 [July 19th, 2011]
- Comprehensive Inpatient Rehabilitation - July 28th, 2011 [July 28th, 2011]
- SCI Treatment Center at the Claremont Club - July 30th, 2011 [July 30th, 2011]
- Spinal Cord Inury Patient at XCell-Center- M. Hasan - August 5th, 2011 [August 5th, 2011]
- Spinal Cord Inury Patient at XCell-Center- K. Potts - August 6th, 2011 [August 6th, 2011]
- Magee Rehabilitation Hospital Foundation and Toyota 100 Cars for Good - August 13th, 2011 [August 13th, 2011]
- SCI_Celine_French_ifting_her_arms.wmv - September 1st, 2011 [September 1st, 2011]
- New Treatment May Help Paralyzed Patients Move Again By Dr.Zaghloul ahmed - September 1st, 2011 [September 1st, 2011]
- Claire Marsh - Spinal Cord Injury Part One - September 6th, 2011 [September 6th, 2011]
- Coping with spinal cord and traumatic brain injuries - September 10th, 2011 [September 10th, 2011]
- Stem Cell Treatment - Spinal Cord Injury (3) - September 15th, 2011 [September 15th, 2011]
- Stem Cell Treatment - Spinal Cord Injury (1) - September 20th, 2011 [September 20th, 2011]
- Stem cell treatment by Adiva Health Care India after Spinal Cord Injury - September 22nd, 2011 [September 22nd, 2011]
- Spinal Cord Injury Documentary: You Will Never Walk Again, Part 1 - September 24th, 2011 [September 24th, 2011]
- Claire Marsh Returns - Spinal Cord Injury Patient - September 25th, 2011 [September 25th, 2011]
- Spinal Cord Injury: Raising awareness about research and treatment for spinal cord injury - September 26th, 2011 [September 26th, 2011]
- Walking after Spinal Cord injury and Stem Cells - September 27th, 2011 [September 27th, 2011]
- New Treatments for Spinal Cord Injuries - October 10th, 2011 [October 10th, 2011]
- Claire Marsh - Spinal Cord Injury Part Two - Video - October 18th, 2011 [October 18th, 2011]
- Stem Cell Treatment for Spinal Cord Injury - Video - November 2nd, 2011 [November 2nd, 2011]
- Stem Cells - Treatment for Spinal Cord Injury - Video - November 2nd, 2011 [November 2nd, 2011]
- (Film Trailer) - The Spinal Cord Journey: Stem Cell Therapy Stories of Recovery - Video - November 27th, 2011 [November 27th, 2011]
- Stem Cell Treatment for T-6 Spinal Cord Injury - Video - December 7th, 2011 [December 7th, 2011]
- What is Project Walk Atlanta - Video - December 13th, 2011 [December 13th, 2011]
- Stem Cells Treatment for Spinal Cord Injuries, Successfully Results, Stem Therapy - Video - December 28th, 2011 [December 28th, 2011]
- Stem Cell Therapy for Spinal Cord Injury, India Mumbai - Video - January 6th, 2012 [January 6th, 2012]
- "April Crave", "Project Walk Spinal Cord Injury Recovery" - Video - January 10th, 2012 [January 10th, 2012]
- "Lori Hammond", "Project Walk Spinal Cord Injury Recovery" - Video - January 23rd, 2012 [January 23rd, 2012]
- "Chad C.""spinal cord Injury treatment" "spinal cord injury" "spinal cord injury recovery" - Video - January 23rd, 2012 [January 23rd, 2012]
- "Hugo Rodovalho", "Client Spotlight Project Walk Spinal Cord Injury Recovery" - Video - January 27th, 2012 [January 27th, 2012]
- "Cecilia V.", "Project Walk Spinal Cord Injury Recovery" - Video - January 27th, 2012 [January 27th, 2012]
- "Roy R.", "Project Walk Spinal Cord Injury Recovery" - Video - January 27th, 2012 [January 27th, 2012]
- "Angela", "Project Walk Spinal Cord Injury Recovery" - Video - January 27th, 2012 [January 27th, 2012]
- "Joey's Story", "Project Walk Spinal Cord Injury Recovery" - Video - January 27th, 2012 [January 27th, 2012]
- "Spinal Cord Injury", "A Story Of One" - Video - January 27th, 2012 [January 27th, 2012]
- Spinal Cord Injuries - The Healing Center Project! - Video - January 28th, 2012 [January 28th, 2012]
- "Crystal H.", "Project Walk Spinal Cord Injury Recovery" - Video - February 3rd, 2012 [February 3rd, 2012]
- "Dave D.", "Project Walk Spinal Cord Injury Recovery" - Video - February 5th, 2012 [February 5th, 2012]
- "Brook", "Project Walk Spinal Cord Injury Recovery" - Video - February 5th, 2012 [February 5th, 2012]
- "Ashley Vargas", "Project Walk Spinal Cord Injury Recovery" - Video - February 6th, 2012 [February 6th, 2012]
- "Nathan Bayer", "Project Walk Spinal Cord Injury Recovery" - Video - February 8th, 2012 [February 8th, 2012]
- "Annette Ross", "Project Walk Spinal Cord Injury Recovery" - Video - February 8th, 2012 [February 8th, 2012]
- "Joe Guintu", "Project Walk Spinal Cord Injury Recovery" - Video - February 8th, 2012 [February 8th, 2012]
- "Trevor Comeau,"Project Walk Spinal Cord Injury Recovery" - Video - February 9th, 2012 [February 9th, 2012]
- "Kyle Eade, "Project Walk Spinal Cord Injury Recovery" - Video - February 11th, 2012 [February 11th, 2012]
- Velomedix Receives IDE Approval to Evaluate the Use of Rapid Therapeutic Hypothermia in the Management of AMI Patients - February 14th, 2012 [February 14th, 2012]
- Neuralstem Announces Closing of $5.2-Million Registered Direct Offering - February 14th, 2012 [February 14th, 2012]
- Chamber May Open Window for Treating Spine - February 15th, 2012 [February 15th, 2012]
- InVivo Therapeutics’ CEO Frank Reynolds Scheduled to Appear on Fox News First and San Antonio Living - February 17th, 2012 [February 17th, 2012]
- High doses of 'load' slows loss of bone in spinal cord injury - February 17th, 2012 [February 17th, 2012]
- InVivo Therapeutics Announces Pricing of Public Offering of Common Stock - February 17th, 2012 [February 17th, 2012]
- High Doses of Load Slows Bone Loss in Spinal Cord Injury - February 21st, 2012 [February 21st, 2012]
- InVivo Therapeutics Announces Full Exercise of Over-Allotment Option - February 22nd, 2012 [February 22nd, 2012]
- InVivo Therapeutics Announces Net $18.1M In Offering - February 22nd, 2012 [February 22nd, 2012]